Regeneron Pharmaceuticals, Inc. (0R2M.L)
USD 732.14
(-1.06%)
USD 732.14
(-1.06%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 7.1 Billion USD | 8.5% |
| 2022 | 6.55 Billion USD | -1.73% |
| 2021 | 6.66 Billion USD | 8.6% |
| 2020 | 6.13 Billion USD | 65.2% |
| 2019 | 3.71 Billion USD | 24.8% |
| 2018 | 2.97 Billion USD | 13.62% |
| 2017 | 2.62 Billion USD | 3.8% |
| 2016 | 2.52 Billion USD | 29.16% |
| 2015 | 1.95 Billion USD | 46.99% |
| 2014 | 1.32 Billion USD | 33.09% |
| 2013 | 998.93 Million USD | 19.62% |
| 2012 | 835.1 Million USD | -0.33% |
| 2011 | 837.85 Million USD | 49.19% |
| 2010 | 561.61 Million USD | 63.05% |
| 2009 | 344.44 Million USD | 37.13% |
| 2008 | 251.18 Million USD | -47.23% |
| 2007 | 475.99 Million USD | 29.18% |
| 2006 | 368.46 Million USD | 19.05% |
| 2005 | 309.49 Million USD | 6.52% |
| 2004 | 290.56 Million USD | -15.02% |
| 2003 | 341.91 Million USD | 39.22% |
| 2002 | 245.59 Million USD | 7.23% |
| 2001 | 229.04 Million USD | 776.08% |
| 2000 | 26.14 Million USD | -4.93% |
| 1999 | 27.5 Million USD | 7.0% |
| 1998 | 25.7 Million USD | -12.88% |
| 1997 | 29.5 Million USD | -3.91% |
| 1996 | 30.7 Million USD | 18.53% |
| 1995 | 25.9 Million USD | -4.43% |
| 1994 | 27.1 Million USD | 41.15% |
| 1993 | 19.2 Million USD | 79.44% |
| 1992 | 10.7 Million USD | 37.18% |
| 1991 | 7.8 Million USD | -40.91% |
| 1990 | 13.2 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 7.37 Billion USD | 3.82% |
| 2024 Q3 | 8.11 Billion USD | 2.98% |
| 2024 Q2 | 7.88 Billion USD | 6.81% |
| 2023 Q1 | 6.56 Billion USD | 0.22% |
| 2023 Q2 | 6.63 Billion USD | 1.14% |
| 2023 FY | 7.1 Billion USD | 8.5% |
| 2023 Q3 | 7.25 Billion USD | 9.33% |
| 2023 Q4 | 7.1 Billion USD | -2.09% |
| 2022 Q2 | 6.51 Billion USD | 1.31% |
| 2022 Q4 | 6.55 Billion USD | 4.99% |
| 2022 FY | 6.55 Billion USD | -1.73% |
| 2022 Q1 | 6.43 Billion USD | -3.48% |
| 2022 Q3 | 6.23 Billion USD | -4.28% |
| 2021 Q3 | 6.41 Billion USD | 0.86% |
| 2021 Q4 | 6.66 Billion USD | 3.94% |
| 2021 Q1 | 5.79 Billion USD | -5.58% |
| 2021 FY | 6.66 Billion USD | 8.6% |
| 2021 Q2 | 6.35 Billion USD | 9.72% |
| 2020 FY | 6.13 Billion USD | 65.2% |
| 2020 Q4 | 6.13 Billion USD | 3.01% |
| 2020 Q1 | 3.62 Billion USD | -2.45% |
| 2020 Q2 | 5.37 Billion USD | 48.19% |
| 2020 Q3 | 5.95 Billion USD | 10.93% |
| 2019 Q3 | 3.43 Billion USD | 0.5% |
| 2019 Q4 | 3.71 Billion USD | 8.17% |
| 2019 Q2 | 3.41 Billion USD | 0.22% |
| 2019 Q1 | 3.41 Billion USD | 14.54% |
| 2019 FY | 3.71 Billion USD | 24.8% |
| 2018 Q3 | 2.93 Billion USD | 6.21% |
| 2018 Q1 | 2.8 Billion USD | 7.05% |
| 2018 FY | 2.97 Billion USD | 13.62% |
| 2018 Q2 | 2.76 Billion USD | -1.41% |
| 2018 Q4 | 2.97 Billion USD | 1.36% |
| 2017 FY | 2.62 Billion USD | 3.8% |
| 2017 Q3 | 2.64 Billion USD | 2.47% |
| 2017 Q4 | 2.62 Billion USD | -1.11% |
| 2017 Q1 | 2.95 Billion USD | 16.92% |
| 2017 Q2 | 2.58 Billion USD | -12.39% |
| 2016 Q4 | 2.52 Billion USD | 8.02% |
| 2016 FY | 2.52 Billion USD | 29.16% |
| 2016 Q2 | 2.12 Billion USD | -0.51% |
| 2016 Q3 | 2.33 Billion USD | 9.79% |
| 2016 Q1 | 2.13 Billion USD | 9.47% |
| 2015 Q2 | 1.18 Billion USD | -3.15% |
| 2015 Q1 | 1.22 Billion USD | -7.7% |
| 2015 Q4 | 1.95 Billion USD | 3.62% |
| 2015 Q3 | 1.88 Billion USD | 58.69% |
| 2015 FY | 1.95 Billion USD | 46.99% |
| 2014 Q4 | 1.32 Billion USD | 11.95% |
| 2014 FY | 1.32 Billion USD | 33.09% |
| 2014 Q1 | 1.04 Billion USD | 5.03% |
| 2014 Q2 | 1.08 Billion USD | 3.63% |
| 2014 Q3 | 1.18 Billion USD | 9.23% |
| 2013 Q3 | 950.24 Million USD | 7.38% |
| 2013 Q2 | 884.92 Million USD | 1.76% |
| 2013 Q1 | 869.65 Million USD | 4.14% |
| 2013 FY | 998.93 Million USD | 19.62% |
| 2013 Q4 | 998.93 Million USD | 5.12% |
| 2012 Q4 | 835.1 Million USD | -2.28% |
| 2012 Q2 | 862.84 Million USD | 1.97% |
| 2012 Q1 | 846.13 Million USD | 0.99% |
| 2012 FY | 835.1 Million USD | -0.33% |
| 2012 Q3 | 854.59 Million USD | -0.96% |
| 2011 Q1 | 556.2 Million USD | -0.96% |
| 2011 Q4 | 837.85 Million USD | 51.02% |
| 2011 FY | 837.85 Million USD | 49.19% |
| 2011 Q2 | 568.83 Million USD | 2.27% |
| 2011 Q3 | 554.77 Million USD | -2.47% |
| 2010 Q1 | 400.88 Million USD | 16.39% |
| 2010 Q2 | 419.42 Million USD | 4.62% |
| 2010 Q3 | 594.36 Million USD | 41.71% |
| 2010 Q4 | 561.61 Million USD | -5.51% |
| 2010 FY | 561.61 Million USD | 63.05% |
| 2009 Q4 | 344.44 Million USD | 7.72% |
| 2009 Q1 | 271.1 Million USD | 7.93% |
| 2009 Q3 | 319.74 Million USD | -3.64% |
| 2009 FY | 344.44 Million USD | 37.13% |
| 2009 Q2 | 331.83 Million USD | 22.4% |
| 2008 FY | 251.18 Million USD | -47.23% |
| 2008 Q2 | 400.22 Million USD | -14.89% |
| 2008 Q3 | 388.95 Million USD | -2.82% |
| 2008 Q4 | 251.18 Million USD | -35.42% |
| 2008 Q1 | 470.27 Million USD | -1.2% |
| 2007 Q2 | 418.52 Million USD | 3.4% |
| 2007 Q3 | 421.69 Million USD | 0.76% |
| 2007 Q4 | 475.99 Million USD | 12.87% |
| 2007 FY | 475.99 Million USD | 29.18% |
| 2007 Q1 | 404.74 Million USD | 9.85% |
| 2006 Q3 | 292.71 Million USD | -0.63% |
| 2006 Q1 | 299.76 Million USD | -3.14% |
| 2006 FY | 368.46 Million USD | 19.05% |
| 2006 Q2 | 294.56 Million USD | -1.74% |
| 2006 Q4 | 368.46 Million USD | 25.88% |
| 2005 Q4 | 309.49 Million USD | 9.4% |
| 2005 Q3 | 282.89 Million USD | 0.36% |
| 2005 Q2 | 281.88 Million USD | -0.92% |
| 2005 Q1 | 284.5 Million USD | -2.08% |
| 2005 FY | 309.49 Million USD | 6.52% |
| 2004 Q3 | 293.81 Million USD | -1.42% |
| 2004 Q2 | 298.04 Million USD | -1.33% |
| 2004 FY | 290.56 Million USD | -15.02% |
| 2004 Q4 | 290.56 Million USD | -1.11% |
| 2004 Q1 | 302.07 Million USD | -11.65% |
| 2003 Q2 | 257.7 Million USD | -2.69% |
| 2003 FY | 341.91 Million USD | 39.22% |
| 2003 Q4 | 341.91 Million USD | -0.69% |
| 2003 Q3 | 344.29 Million USD | 33.6% |
| 2003 Q1 | 264.82 Million USD | 7.83% |
| 2002 Q3 | 237.8 Million USD | 4.62% |
| 2002 Q4 | 245.59 Million USD | 3.28% |
| 2002 Q1 | 229.38 Million USD | 0.15% |
| 2002 Q2 | 227.29 Million USD | -0.91% |
| 2002 FY | 245.59 Million USD | 7.23% |
| 2001 Q4 | 229.04 Million USD | 864.71% |
| 2001 FY | 229.04 Million USD | 776.08% |
| 2001 Q1 | 24.77 Million USD | -5.24% |
| 2001 Q2 | 23 Million USD | -7.16% |
| 2001 Q3 | 23.74 Million USD | 3.22% |
| 2000 FY | 26.14 Million USD | -4.93% |
| 2000 Q1 | 26.43 Million USD | -3.86% |
| 2000 Q3 | 25.34 Million USD | -3.06% |
| 2000 Q2 | 26.14 Million USD | -1.11% |
| 2000 Q4 | 26.14 Million USD | 3.14% |
| 1999 Q1 | 25.9 Million USD | 0.78% |
| 1999 FY | 27.5 Million USD | 7.0% |
| 1999 Q3 | 23.9 Million USD | -2.05% |
| 1999 Q2 | 24.4 Million USD | -5.79% |
| 1999 Q4 | 27.5 Million USD | 15.06% |
| 1998 Q1 | 26 Million USD | -11.86% |
| 1998 Q2 | 27.3 Million USD | 5.0% |
| 1998 Q3 | 25.5 Million USD | -6.59% |
| 1998 Q4 | 25.7 Million USD | 0.78% |
| 1998 FY | 25.7 Million USD | -12.88% |
| 1997 Q1 | 28.1 Million USD | -8.47% |
| 1997 FY | 29.5 Million USD | -3.91% |
| 1997 Q3 | 26.5 Million USD | -11.96% |
| 1997 Q4 | 29.5 Million USD | 11.32% |
| 1997 Q2 | 30.1 Million USD | 7.12% |
| 1996 Q1 | 24.1 Million USD | -6.95% |
| 1996 Q4 | 30.7 Million USD | 16.29% |
| 1996 Q3 | 26.4 Million USD | -0.38% |
| 1996 FY | 30.7 Million USD | 18.53% |
| 1996 Q2 | 26.5 Million USD | 9.96% |
| 1995 Q1 | 22.3 Million USD | -17.71% |
| 1995 Q3 | 21.2 Million USD | -11.67% |
| 1995 Q4 | 25.9 Million USD | 22.17% |
| 1995 Q2 | 24 Million USD | 7.62% |
| 1995 FY | 25.9 Million USD | -4.43% |
| 1994 Q2 | 29.1 Million USD | 50.78% |
| 1994 Q1 | 19.3 Million USD | 0.52% |
| 1994 FY | 27.1 Million USD | 41.15% |
| 1994 Q4 | 27.1 Million USD | 10.16% |
| 1994 Q3 | 24.6 Million USD | -15.46% |
| 1993 Q3 | 15.8 Million USD | 12.86% |
| 1993 FY | 19.2 Million USD | 79.44% |
| 1993 Q2 | 14 Million USD | 9.38% |
| 1993 Q1 | 12.8 Million USD | 19.63% |
| 1993 Q4 | 19.2 Million USD | 21.52% |
| 1992 Q4 | 10.7 Million USD | -1.83% |
| 1992 Q3 | 10.9 Million USD | 15.96% |
| 1992 Q2 | 9.4 Million USD | 2.17% |
| 1992 Q1 | 9.2 Million USD | 17.95% |
| 1992 FY | 10.7 Million USD | 37.18% |
| 1991 Q3 | 5.6 Million USD | -5.08% |
| 1991 FY | 7.8 Million USD | -40.91% |
| 1991 Q2 | 5.9 Million USD | 0.0% |
| 1991 Q4 | 7.8 Million USD | 39.29% |
| 1990 Q4 | 13.2 Million USD | 0.0% |
| 1990 FY | 13.2 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | -4636.298% |
| Dynavax Technologies Corporation | 375.02 Million USD | -1795.105% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -1357.983% |
| Perrigo Company plc | 6.04 Billion USD | -17.644% |
| Illumina, Inc. | 4.36 Billion USD | -62.783% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 86.302% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -3530.925% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 89.678% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 65.448% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -2671.026% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -18957.975% |
| Waters Corporation | 3.47 Billion USD | -104.432% |
| Biogen Inc. | 12.04 Billion USD | 40.997% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -8521.669% |
| Evolus, Inc. | 209.68 Million USD | -3289.385% |
| Adicet Bio, Inc. | 37.12 Million USD | -19046.282% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -10236.247% |
| bluebird bio, Inc. | 424.62 Million USD | -1573.74% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -975.546% |
| FibroGen, Inc. | 585.72 Million USD | -1113.379% |
| Agilent Technologies, Inc. | 4.91 Billion USD | -44.512% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -20103.76% |
| Homology Medicines, Inc. | 118.53 Million USD | -5895.883% |
| Geron Corporation | 146.12 Million USD | -4763.646% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | -75.461% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -1050.564% |
| Myriad Genetics, Inc. | 312.9 Million USD | -2171.365% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -35309.795% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -2733.682% |
| Zoetis Inc. | 9.29 Billion USD | 23.538% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -14352.375% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | -102.742% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | -276.026% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | -38.007% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -14570.451% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | -172.994% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -2584.609% |
| Verastem, Inc. | 71.18 Million USD | -9883.985% |
| Nektar Therapeutics | 267.04 Million USD | -2561.377% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -1689.034% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -17567.926% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | -195.484% |
| OPKO Health, Inc. | 622.47 Million USD | -1041.741% |
| Exelixis, Inc. | 678.44 Million USD | -947.557% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -597.185% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -6090.207% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -56602.569% |
| uniQure N.V. | 624.01 Million USD | -1038.924% |
| Imunon, Inc. | 8.53 Million USD | -83214.704% |
| Blueprint Medicines Corporation | 918.64 Million USD | -673.654% |
| Insmed Incorporated | 1.66 Billion USD | -327.685% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | -330.874% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -5536.127% |
| TG Therapeutics, Inc. | 169.08 Million USD | -4103.271% |
| Incyte Corporation | 1.59 Billion USD | -346.35% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -499.452% |